275 results on '"Bassez, G."'
Search Results
2. P351 Rhabdomyolysis and muscle biopsy outcomes: a single center retrospective cohort
3. P387 Initiation and follow-up of mexiletine treatment in adult myotonic dystrophy patients: an expert opinion
4. VP429 Impaired skeletal muscle strength in adult patients with laminopathies
5. P395 Recommendations of an expert group for cardiac assessment of non-dystrophic myotonic adult patients treated with mexiletine
6. Scapular dyskinesis in myotonic dystrophy type 1: clinical characteristics and genetic investigations
7. Unravelling the myotonic dystrophy type 1 clinical spectrum: A systematic registry-based study with implications for disease classification
8. Multiple acyl-CoA dehydrogenase deficiency (MADD) as a cause of late-onset treatable metabolic disease
9. VP.26 Potential of the MyoSuit, a lightweight wearable lower-limb cable-actuated exoskeleton in patients with neuromuscular disorders: preliminary findings
10. VP.27 Potential of the Keeogo+, a lightweight wearable powered assistive exoskeleton in patients with neuromuscular disorders: preliminary findings
11. Clinical improvement of DM1 patients reflected by reversal of disease-induced gene expression in blood
12. Development and validation of a motor function classification in patients with neuromuscular disease: The NM-Score
13. Myotonic dystrophy type 2 (DM2) and related disorders: Report of the 180th ENMC Workshop including guidelines on diagnostics and management 3–5 December 2010, Naarden, The Netherlands
14. REGISTRIES AND CARE OF NMD
15. Improved cardiac outcomes by early treatment with angiotensin-converting enzyme inhibitors in becker muscular dystrophy
16. Atrial flutter in myotonic dystrophy type 1: patient characteristics and clinical outcome: 2.29
17. Late-onset cervicoscapular muscle atrophy and weakness after radiotherapy for Hodgkin disease: a case series
18. Myofiber HLA-DR expression: a distinctive biomarker for antisynthetase myositis: OS1213
19. Assessment of calf muscle contraction by diffusion tensor imaging
20. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry
21. 222nd ENMC International Workshop: Myotonic dystrophy, developing a European consortium for care and therapy, Naarden, The Netherlands, 1-2 July 2016
22. AUTOIMMUNE MYOPATHIES
23. FSHD / OPMD / MYOTONIC DYSTROPHY
24. FSHD / OPMD / MYOTONIC DYSTROPHY
25. DMD – BIOMARKERS & OUTCOME MEASURES
26. Central and peripheral components of exercise-related fatigability in myotonic dystrophy type 1
27. P.100Pseudo-increment at repetitive nerve stimulation (Arzel's sign): a new tool for Brody myopathy diagnosis
28. P.335Phenotypic and genomic characterization as predictors of DMD 45 to 55 multi-exon skipping therapy
29. Eye Symptoms and Ophthalmologic Care in a Myotonic Dystrophy Type 1 (DM1)
30. Eight years after an international workshop on myotonic dystrophy patient registries: case study of a global collaboration for a rare disease (vol 13, 155, 2018)
31. Flow cytometry (FC) assesses skeletal muscle CD8 T-cell enrichment in inflammatory myopathies: SC228
32. rbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
33. Syndrome Myotonique – Analyse des hospitalisations à partir de la base PMSI
34. Atteintes rétiniennes dans la DM1 : revue de la littérature et présentation d’un projet basé sur DM-Scope
35. CONGENITAL MYASTHENIC SYNDROMES AND MYASTHENIA
36. FSHD / OPMD / EDMD / DMI
37. PMS65 - MYOTONIC DISORDERS: ANALYSIS FROM THE FRENCH DRG-BASED INFORMATION SYSTEM (PMSI)
38. Incidence and predictors of venous thromboembolism in inherited myopathies: A higher risk in myotonic dystrophy
39. Survival in myotonic dystrophy type 1 predicted by the new DM1 survival risk score
40. A large multicenter study of pediatric myotonic dystrophy type 1 for evidence-based management
41. Associations between grip strength, myotonia and CTG expansion in myotonic dystrophy type 1
42. Association between mutation size and cardiac involvement in myotonic dystrophy type 1: an analysis of the DM1-heart registry
43. Venous thromboembolism in adult patients with inherited myopathies: a high-risk in myotonic dystrophy
44. Muscular fat fraction correlates with functionality in myotonic dystrophy type 1
45. Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients
46. Effect of enzyme replacement therapy with alglucosidase alfa (Myozyme®) in 12 patients with advanced late-onset Pompe disease
47. A large nationwide multicenter observational study: Characterizing myotonic dystrophy type 1 spectrum in pediatric patients
48. Association between mutation size and cardiac involvement in myotonic dystrophy type 1: when size matters
49. Correlation between mutation size and cardiac involvement in myotonic dystrophy type 1: An analysis of the DM1-heart registry
50. Distinctive IFNγ signature in anti-synthetase syndrome and inclusion body myositis compared to dermatomyositis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.